Approved indications: Duavee is FDA-approved for (1) treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause and (2) prevention of postmenopausal osteoporosis in postmenopausal women with a uterus.

Off-label uses: Duavee is primarily used for its approved menopausal symptom and osteoporosis-prevention indications, and it does not have widely accepted, well-studied off-label uses.

Efficacy expectations:

• Hot flashes and night sweats often begin to improve within 1 to 2 weeks, with maximum benefit usually seen over about 4 to 12 weeks of regular use.
• For bone protection, Duavee helps slow bone loss and can increase bone mineral density over months to years compared with no treatment, helping reduce fracture risk when used as part of an overall osteoporosis prevention plan.
• Compared with traditional estrogen plus progestin therapy, Duavee provides similar relief of hot flashes and bone benefits while using bazedoxifene instead of a progestin, which may lead to less uterine bleeding and fewer progestin-related side effects in many women.

Typical dosing and how to take: The usual dose is one Duavee tablet containing 0.45 mg conjugated estrogens/20 mg bazedoxifene taken by mouth once daily, with or without food, at about the same time each day, swallowing the tablet whole without crushing or chewing.

Special dosing instructions: Use the lowest effective dose for the shortest duration consistent with treatment goals; Duavee is intended only for postmenopausal women with a uterus and should not be taken together with other systemic estrogens, progestins, or selective estrogen receptor modulators unless specifically directed by a clinician.

Missed dose guidance: If a dose is missed, take it as soon as remembered on the same day; if it is almost time for the next dose, skip the missed dose and resume the regular schedule, and do not take two tablets at once to make up for a missed dose.

Overdose: In case of overdose, seek medical help or contact a poison control center immediately; symptoms may include nausea, vomiting, breast tenderness, or vaginal bleeding.

Common side effects: Common effects can include muscle spasms, nausea, diarrhea, upset stomach or abdominal pain, throat or neck pain, dizziness, and joint pain; these are often mild to moderate and may appear in the first weeks of treatment, sometimes improving as the body adjusts.

Serious or rare adverse effects:

• Blood clots in the legs or lungs (deep vein thrombosis, pulmonary embolism) or stroke, which may present with leg swelling or pain, sudden shortness of breath, chest pain, or sudden weakness or trouble speaking.
• Heart attack symptoms such as chest pressure or pain radiating to the arm, jaw, or back.
• Vision changes or sudden partial loss of vision that could signal retinal vascular problems.
• Unusual vaginal bleeding, pelvic pain, or breast changes such as a new lump, which require prompt evaluation.
• Severe allergic reactions (swelling of face, lips, tongue, or throat, trouble breathing, or hives) needing emergency care.

Warnings and precautions:

• Duavee carries estrogen-related risks, including increased risks of blood clots, stroke, heart attack, and probable dementia in some women aged 65 years and older; it should be used at the lowest effective dose for the shortest duration needed.
• It is contraindicated in pregnancy and should not be used while breastfeeding, because it can harm a developing baby and may affect milk production.
• It should not be used in women with a history of breast cancer or estrogen-dependent tumors, unexplained vaginal bleeding, active or past blood clots, stroke, heart attack, severe liver disease, or known clotting disorders.
• Caution is needed in women with risk factors such as obesity, smoking, high blood pressure, high cholesterol, diabetes, or a strong family history of blood clots or hormone-sensitive cancers.

Safety compared with similar drugs: Duavee shares many of the same boxed warnings and risks as other systemic estrogen therapies, but uses bazedoxifene instead of a progestin to protect the uterus, which may reduce the chance of progestin-related side effects and abnormal bleeding compared with estrogen plus traditional progestin regimens.

Reporting side effects and safety updates: Side effects should be reported to a healthcare professional and can also be reported to the FDA MedWatch program (by phone at 1-800-FDA-1088 or online); current safety information is available through the FDA and the manufacturer’s prescribing information.

Drug and supplement interactions:

• Using Duavee with other systemic estrogens, progestins, or selective estrogen receptor modulators (such as raloxifene or tamoxifen) is generally not recommended unless specifically instructed.
• Bile acid sequestrants (such as cholestyramine) can reduce absorption of conjugated estrogens and may decrease the effect of Duavee if taken at the same time.
• Estrogens can affect how some medicines work, such as blood thinners (for example warfarin) or thyroid hormone replacement, so dose adjustments and monitoring may be needed.
• Always review nonprescription medicines, herbal products (including St. John’s wort or high-dose phytoestrogens), and vitamins with a healthcare professional, as they may influence hormone levels or clotting risk.
• Alcohol and smoking can increase overall cardiovascular and clotting risks, which is important for women taking estrogen-containing therapies.

Food and test interactions: Duavee can be taken with or without food, and there are no specific food restrictions, but estrogens may alter some laboratory test results (such as thyroid function tests or certain hormone levels).

Precautions and situations where use may be unsafe:

• History of blood clots, stroke, heart attack, severe liver disease, or known inherited clotting disorders generally makes Duavee unsafe.
• Women with a history of breast cancer, estrogen-dependent cancers, or unexplained vaginal bleeding should not use Duavee unless a specialist specifically advises otherwise.
• Caution is needed in women with risk factors such as obesity, smoking, high blood pressure, diabetes, high cholesterol, or strong family history of venous thromboembolism or hormone-sensitive cancers.
• Duavee is not indicated for children, premenopausal women, men, or during pregnancy or breastfeeding.

Monitoring needs: Regular follow-up should typically include blood pressure checks, breast exams and mammograms as recommended for age and risk, pelvic exams and evaluation of any abnormal vaginal bleeding, and periodic reassessment of bone health and overall cardiovascular and clotting risk to decide whether to continue therapy.

Q: Who is Duavee for?
A: Duavee is for postmenopausal women with a uterus who need treatment for moderate to severe hot flashes or prevention of postmenopausal osteoporosis, as determined by their healthcare provider.

Q: How long can I safely take Duavee?
A: The duration is individualized, but Duavee should generally be used at the lowest effective dose for the shortest time needed, with your provider regularly reassessing whether you still need it.

Q: When will my hot flashes start to improve on Duavee?
A: Many women notice some relief within 1 to 2 weeks, with full benefit often taking up to several weeks of daily use.

Q: Can I take Duavee with my other hormone therapy?
A: Duavee is usually not taken together with other systemic estrogens, progestins, or drugs like raloxifene or tamoxifen, so you should not combine them unless your clinician specifically instructs you to switch or overlap.

Q: Does Duavee increase my risk of blood clots or stroke?
A: Like other systemic estrogen therapies, Duavee can increase the risk of blood clots and stroke, especially in women with other risk factors, so your provider will review your medical history and help you weigh benefits and risks.

Q: Do I still need mammograms while taking Duavee?
A: Yes, you should continue regular breast exams and mammograms as recommended for your age and risk level while taking Duavee.

Storage: Store Duavee tablets at room temperature (about 68°F to 77°F/20°C to 25°C), in the original blister packaging, away from moisture, heat, and direct light, and out of reach of children and pets.

Disposal: Do not use Duavee past the expiration date; dispose of unused or expired tablets through a medicine take-back program if available, or follow local pharmacy or community guidance, and do not flush tablets down the toilet or pour them into drains unless specifically instructed.